

CE

SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography)

[Product name]

SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography)

[Model]

1 test/kit; 5 tests/kit; 10 tests/kit; 25 tests/kit; 50 tests/kit.

【Intended Use】

The product is intended for the qualitative detection of antigen against SARS-CoV-2 in clinical samples (nasal swab).

[Summary]

Coronavirus, as a large virus family, is a single positive stranded RNA virus with envelope. The virus is known to cause major illnesses such as colds, Middle East Respiratory Syndrome (MERS), and Severe Acute Respiratory Syndrome (SARS). The core protein of SARS-CoV-2 is the N protein (Nucleocapsid), which is a protein component located inside the virus. It is relatively conserved among β -coronaviruses and is often used as a tool for the diagnosis of coronaviruses. ACE2, as a key receptor for SARS-CoV-2 to enter cells, is of great significance for the research of viral infection mechanism.

[Principle]

The current test card is based on the specific antibody-antigen reaction and immunoanalysis technology. The test card contains colloidal gold labeled SARS-CoV-2 N protein monoclonal antibody which is pre-coated on the combination pad, matched SARS-CoV-2 N protein monoclonal antibody immobilized on the Test area (T) and corresponding antibody in the quality control area (C).

During testing, the N protein in the sample combines with the colloidal gold labeled SARS-CoV-2 N protein monoclonal antibody which is pre-coated on the combination pad. The conjugates

migrate upward under capillary effect, and subsequently captured by the N protein monoclonal antibody immobilized in the Test area (T). The higher the contents of N protein in the sample, the more the conjugates captures and the darker the color in the test area is. If there is no virus in the sample or the virus content is lower than the detection limit, then there is no color demonstrated in the test area (T). Regardless of the presence or absence of the virus in the sample, a purple stripe will appear in the quality control area (C). The purple stripe in the quality control area (C) is a criterion for the judgment of whether or not there is enough sample and whether or not the chromatography procedure is normal.

【Component】

The product consists of test cards, Instructions for use, sample treatment solution. And in each test card bag, it includes one SARS-CoV-2 antigen detection card and one package of desiccant.

Model	Test card	Instructions for use	Sample treatment solution		
1 test/kit	1 test	1	1 ml		
5 tests/kit	5 tests	1	1ml		
10tests/kit	10 tests	1	2ml		
25 tests/kit	25 tests	1	3ml		
50 tests/kit	50 tests	1	6ml		
For each test card bag, it contains one test card and one package of					
desiccant.					

The test card consists of gold standard mat (coated with colloidal gold labelled SARS-CoV-2 N protein monoclonal antibody), sample mat, nitrocellulose membrane (Test area (T) is coated with an SARS-CoV-2 N protein monoclonal antibody; the quality control area (C) is coated with goat anti-mouse antibody), absorbing paper, and hydrophobic stiff card.

[Storage and Stability]

It should be stored at 4°C~ 30°C, be kept dry and away from sunlight. The shelf life is 12 months. For per test card, it should be used within 1 hour after unsealing. Production Date and Expiration date are shown in the package label.

[Sample Requirements]

The product is used to test the human nasal swab sample. Sample collection: During the collection procedures for samples, take care to make proper protection, and avoid direct contact with the sample. In case of accidental contact, disinfection treatment should be carried out in time and necessary measures should be taken. Nasal swab

sample: gently and slowly insert the swab into the nasopharynx through the nasal cavity. When resistance is encountered, the swab will arrive at the posterior nasopharynx. After a few seconds of suction, gently rotate the swab, then take out the swab to obtain the nasal swab sample. Sample preservation: after sample collection, please complete the test within 1 hour.

The sample should come to room temperature before testing.

[Test Method]


Please read the instruction for use carefully before performing the test. Before testing, restore the reagents and sample to room temperature.

1. Remove the test card from the test card bag and use it within 1 hour, especially in the environment with room temperature higher than $30 \circ C$ or in high humidity.

2. Place the test card on a clean platform. Drip 5 drops of the sample treatment solution to well A.

3. Thread the swab head through the bottom of well B into well A and rotate it two rounds clockwise and counterclockwise respectively in the sample treatment solution.

4. Remove the protective cover of the fixing glue. Stick the left and right sides together and start timing. Wait until the purple band appears. The test result should be read within 15-20 minutes.



【The Explanation of the Testing Results】】

• Positive (+): There appear purple stripes in both quality control area (C) and either test area (T).


• Negative (-): There is only one purple stripe in the quality control area (C), and without purple stripe in either test area (T).



ontrol Line

oct Line

• Invalid: There is no purple stripe in the quality control area (C), or there is blue stripe in the quality control area (C), indicating incorrect operating procedures or the test card has already deteriorated. Under this condition, it must read the instruction for use again carefully, and then use the new test card to test again. If the problem still exists, stop using the products with same lot number and contact the local suppliers immediately.



[Limitation of Procedure]

1. The test results of this product should be comprehensively judged by the physician in combination with other clinical information, and should not be used as the only criterion;

2. The product is used to test the SARS-CoV-2 antigen of the clinical sample.

[Product Performance Index]

1 Physical Property

1.1 Appearance

The test card should be clean and integral, no burrs, no damage, no pollution; the material should be firmly attached; the label should be clear and not damaged. The sample dilution should be clear without impurities and flocs.

1.2 Liquid migration speed

The liquid migration speed should be no less than 10mm/min.

1.3 Membrane Strip Width

The membrane strip width of the testing card should be≥2.5mm.

1.4 The preparation quantity of the diluent for the samples

The volume of the diluents for the sample is no less than the indicated value.

2 Detection Limit

For the detection of sensitivity reference material, the positive detection rate should be no less than 90%.

3 Negative reference products compliance rate

For the detection of negative reference material, the negative detection rate should be 100%.

4 Positive reference products compliance rate

For the detection of positive reference material, the positive detection rate should be 100%.

5 Repeatability

For the detection of enterprise reference material P2 and P4, the results should be positive and the color rendering should be uniform. 6 Analytical Specificity

6.1 Cross-reactivity: This test device has no cross reactivity with endemicity human coronavirus OC43, influenza a virus, influenza B virus, respiratory syncytial virus, adenovirus, EB virus, measles virus, cytomegalovirus, rotavirus, Norovirus, mumps virus, varicella zoster virus, mycoplasma pneumoniae, Human metapneumovirus.

6.2 Interfering substances: The test results do not be interfered with the substance at the following concentration:

bilirubin concentration \leq 250 µmol/l; triglycerides concentration \leq 15 mmol/l;hemoglobin concentration \leq 10 g/dL; rheumatoid factor concentration \leq 80RU/ml; anti-mitochondrial antibody concentration \leq 80 U/mL; the total IgG concentration \leq 14g/L.

The test results do not be influenced by the following substance: α -interferon, zanamivir, ribavirin, oseltamivir, and paramivir, Lopinavir, ritonavir, abidol, levofloxacin, azithromycin, ceftriaxone, meropenem, tobramycin, histamine hydrochloride, phenylephrine, oxymetazoline, sodium chloride (containing Preservatives), beclomethasone, dexamethasone, flunisolide, triamcinolone, budesonide, mometasone and fluticasone.

(Precautions)

1. The test is only suitable for professionals to use in vitro auxiliary diagnosis. Do not use expired products.

2. Do not freeze or use after the expiration date (see the packaging for the expiration date).

3. Avoid excessive temperature and humidity in the experimental environment. The reaction temperature should be $15-30 \degree C$ and the humidity should be below 70%.

4. The test card bag contains desiccant, and it should not be taking orally.

5. When testing, please wear protective clothing, medical mask, gloves and goggles.

6. Do not use the test card with broken single packaging, unclear marks, and past the expiration date.

7. Dispose of used specimens, test cards and other waste in accordance with relevant local laws and regulations.

[Explanation of Symbols]

	DO NOT USE IF PACKAGE IS DAMAGED	Ĩ	CONSULT INSTRUCTIONS FOR USE
8	DO NOT REUSE		USE-BY DATE
an Arm	TEMPERATURE LIMIT	M	DATE OF MANUFACTURER
	MANUFACTURER	LOT	BATCH CODE
紊	KEEP AWAY FROM SUNLIGHT	Ť	KEEP DRY
IVD	IN VITRO DIAGNOSTIC MEDICAL DEVICE	CE	CE MARK
EC REP	AUTHORIZED REPRESENTATIVE IN THE EUROPEAN COMMUNITY		

[Basic information]



Beijing Lepu Medical Technology Co., Ltd. Address: 3th Floor and 5th Floor Building 7-1 No.37 Chaoqian Road, Changping District, Beijing, 102200, P.R. China Tel: +86-10-80123964 Email: lepuservice@lepumedical.com Web: en.lepumedical.com

EC REP Lepu Medical (Europe) Cooperatief U.A.

Abe Lenstra Boulevard 36, 8448 JB, Heerenveen, The Netherlands Tel: +31-515-573399 Fax: +31-515-760020

Approval Date and Revision Date of the Instruction: Approved on 2nd, Sept., 2020; Version number: CE-InCG27 REV.01